iDose

Glaukos Corp (NYSE: GKOS) announced the submission of a pre-market approval application for its iStent inject device on Wednesday. The Analyst Cantor Fitzgerald's Elemer Piros maintains an Overweight rating on Glaukos' stock with a price target boosted from $48 to $60. The Thesis...